The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Prognostic factors contributing to long-term survivorship in patients with hepatobiliary cancers
Stephen L. Chan, MBBS MRCP, FHKCP, FHKAM, FRCP, The Chinese University of Hong Kong, Hong Kong, China, discusses the prognostic factors associated with long-term survival in patients treated with immunotherapies for hepatobiliary cancers, referencing data from the Phase III HIMALAYA trial (NCT03298451). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
